Rayence Co., Ltd.

KOSDAQ:A228850 Stock Report

Market Cap: ₩102.4b

Rayence Valuation

Is A228850 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A228850 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A228850 (₩6530) is trading below our estimate of fair value (₩42632.84)

Significantly Below Fair Value: A228850 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A228850?

Key metric: As A228850 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A228850. This is calculated by dividing A228850's market cap by their current earnings.
What is A228850's PE Ratio?
PE Ratio9.2x
Earnings₩11.21b
Market Cap₩102.44b

Price to Earnings Ratio vs Peers

How does A228850's PE Ratio compare to its peers?

The above table shows the PE ratio for A228850 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average30.6x
A056090 Innosys
59.9xn/a₩119.8b
A208370 SELVAS Healthcare
31.5xn/a₩121.5b
A302550 RemedLtd
24.4xn/a₩119.3b
A065510 Huvitz
6.7xn/a₩84.8b
A228850 Rayence
9.2x20.7%₩102.4b

Price-To-Earnings vs Peers: A228850 is good value based on its Price-To-Earnings Ratio (9.2x) compared to the peer average (30.6x).

Price to Earnings Ratio vs Industry

How does A228850's PE Ratio compare vs other companies in the KR Medical Equipment Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
A035610 Solborn
2.6xn/aUS$67.90m
No more companies available in this PE range
A228850 9.2xIndustry Avg. 12.2xNo. of Companies6PE01224364860+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: A228850 is good value based on its Price-To-Earnings Ratio (9.2x) compared to the KR Medical Equipment industry average (12.2x).

Price to Earnings Ratio vs Fair Ratio

What is A228850's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A228850 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.2x
Fair PE Ratio11.4x

Price-To-Earnings vs Fair Ratio: A228850 is good value based on its Price-To-Earnings Ratio (9.2x) compared to the estimated Fair Price-To-Earnings Ratio (11.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A228850 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩6,530.00
₩10,500.00
+60.8%
4.8%₩11,000.00₩10,000.00n/a2
Nov ’25₩6,810.00
₩10,500.00
+54.2%
4.8%₩11,000.00₩10,000.00n/a2
Oct ’25₩7,060.00
₩10,500.00
+48.7%
4.8%₩11,000.00₩10,000.00n/a2
Sep ’25₩7,290.00
₩10,500.00
+44.0%
4.8%₩11,000.00₩10,000.00n/a2
Aug ’25₩7,940.00
₩11,500.00
+44.8%
4.3%₩12,000.00₩11,000.00n/a2
Jul ’25₩8,120.00
₩11,500.00
+41.6%
4.3%₩12,000.00₩11,000.00n/a2
Jun ’25₩8,200.00
₩11,500.00
+40.2%
4.3%₩12,000.00₩11,000.00n/a2
Aug ’24₩10,370.00
₩16,000.00
+54.3%
6.3%₩17,000.00₩15,000.00₩7,940.002
Jul ’24₩11,140.00
₩16,000.00
+43.6%
6.3%₩17,000.00₩15,000.00₩8,120.002
Jun ’24₩11,480.00
₩16,000.00
+39.4%
6.3%₩17,000.00₩15,000.00₩8,200.002
May ’24₩11,760.00
₩16,000.00
+36.1%
6.3%₩17,000.00₩15,000.00₩8,610.002
Apr ’24₩11,600.00
₩16,000.00
+37.9%
6.3%₩17,000.00₩15,000.00₩9,000.002
Mar ’24₩12,010.00
₩16,000.00
+33.2%
6.3%₩17,000.00₩15,000.00₩9,150.002
Feb ’24₩12,130.00
₩14,500.00
+19.5%
3.4%₩15,000.00₩14,000.00₩9,100.002
Jan ’24₩11,000.00
₩14,500.00
+31.8%
3.4%₩15,000.00₩14,000.00₩9,350.002
Dec ’23₩10,950.00
₩14,500.00
+32.4%
3.4%₩15,000.00₩14,000.00₩9,100.002
Nov ’23₩9,620.00
₩14,500.00
+50.7%
3.4%₩15,000.00₩14,000.00₩9,090.002

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Boditech Med

₩347.2b

Offers instruments and diagnostic reagents in South Korea and internationally.

A206640

₩15,760.00

7D

-2.1%

1Y

-12.9%

Vieworks

₩200.2b

Develops, manufactures, and sells imaging systems and solutions.

A100120

₩21,000.00

7D

3.4%

1Y

-24.2%

Access Bio

₩188.3b

Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.

A950130

₩5,570.00

7D

2.0%

1Y

-37.1%